SG/CALL/NOVO-NORDISK B/1250/0.1/19.12.25 | Market Closed - Bid/Ask 20:51:14 19/06/2024 BST | Pre-market 07:02:05 | |||
| 1.42 EUR | 0.00% |
|
1.435 | +1.06% |
| Current month | +23.48% | ||
| 1 month | +19.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 19/06/24 | 1.42 | 0.00% |
| 18/06/24 | 1.42 | -0.70% |
| 17/06/24 | 1.43 | -6.54% |
| 14/06/24 | 1.53 | +4.08% |
| 13/06/24 | 1.47 | -2.65% |
Real-time Boerse Frankfurt Warrants
Last update June 19, 2024 at 08:51 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU9B0D |
| ISIN | DE000SU9B0D8 |
| Date issued | 14/02/2024 |
| Strike | 1,250 kr |
| Maturity | 19/12/2025 (548 Days) |
| Parity | 10 : 1 |
| Emission price | 1.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.64 € |
|---|---|
| Lowest since issue | 0.94 € |
| Spread | 0.03 € |
| Spread % | 2.04% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984.2
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.07%
- Stock Market
- Warrants
- Warrant
